$629 Million is the total value of SECTOR GAMMA AS's 26 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABT | Buy | ABBOTT LABS | $58,561,000 | +56.1% | 1,318,642 | +35.0% | 9.31% | +32.0% |
| LLY | Sell | LILLY ELI & CO | $55,626,000 | +13.4% | 661,350 | -0.9% | 8.85% | -4.1% |
| BAX | Buy | BAXTER INTL INC | $53,739,000 | +27.2% | 1,036,233 | +8.8% | 8.55% | +7.5% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $42,546,000 | +62.0% | 782,390 | +74.1% | 6.77% | +37.0% |
| PKI | PERKINELMER INC | $36,195,000 | +11.3% | 623,408 | 0.0% | 5.76% | -5.9% | |
| BSX | Buy | BOSTON SCIENTIFIC CORP | $35,412,000 | +30.4% | 1,423,880 | +13.4% | 5.63% | +10.2% |
| ANTM | Buy | ANTHEM INC | $33,838,000 | +67.2% | 204,610 | +45.3% | 5.38% | +41.3% |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $33,110,000 | +9.8% | 1,940,778 | -1.6% | 5.27% | -7.2% |
| SHPG | Buy | SHIRE PLCsponsored adr | $31,494,000 | +25.8% | 180,761 | +23.0% | 5.01% | +6.3% |
| GILD | Buy | GILEAD SCIENCES INC | $30,461,000 | +18.4% | 448,490 | +24.8% | 4.84% | +0.1% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $29,202,000 | +18.7% | 267,050 | -20.0% | 4.64% | +0.3% |
| MASI | Sell | MASIMO CORP | $24,081,000 | +14.1% | 258,218 | -17.5% | 3.83% | -3.5% |
| BIO | BIO RAD LABS INCcl a | $22,733,000 | +9.4% | 114,042 | 0.0% | 3.62% | -7.6% | |
| IART | Buy | INTEGRA LIFESCIENCES HLDGS C | $20,569,000 | -14.7% | 488,230 | +73.6% | 3.27% | -27.9% |
| PDCO | PATTERSON COMPANIES INC | $17,469,000 | +10.2% | 386,232 | 0.0% | 2.78% | -6.8% | |
| MCK | MCKESSON CORP | $17,080,000 | +5.6% | 115,200 | 0.0% | 2.72% | -10.8% | |
| PRGO | New | PERRIGO CO PLC | $16,421,000 | – | 247,340 | +100.0% | 2.61% | – |
| CI | Sell | CIGNA CORPORATION | $12,345,000 | -2.9% | 84,270 | -11.5% | 1.96% | -17.9% |
| LH | New | LABORATORY CORP AMER HLDGS | $12,037,000 | – | 83,900 | +100.0% | 1.91% | – |
| LPNT | LIFEPOINT HEALTH INC | $10,789,000 | +15.3% | 164,714 | 0.0% | 1.72% | -2.5% | |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $10,103,000 | -21.5% | 756,765 | -11.5% | 1.61% | -33.6% |
| IPXL | Buy | IMPAX LABORATORIES INC | $6,759,000 | +2.2% | 534,311 | +7.0% | 1.08% | -13.6% |
| OMI | Sell | OWENS & MINOR INC NEW | $5,047,000 | -33.2% | 145,874 | -31.9% | 0.80% | -43.5% |
| LXRX | New | LEXICON PHARMACEUTICALS INC | $4,765,000 | – | 332,300 | +100.0% | 0.76% | – |
| THC | TENET HEALTHCARE CORP | $4,464,000 | +19.3% | 252,080 | 0.0% | 0.71% | +0.9% | |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $3,923,000 | -59.8% | 28,974 | -57.4% | 0.62% | -66.0% |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -48,500 | -100.0% | -1.12% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -520,091 | -100.0% | -1.46% | – |
| MRK | Exit | MERCK & CO INC NEW | $0 | – | -283,410 | -100.0% | -3.14% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2017-06-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BOSTON SCIENTIFIC CORP | 40 | Q1 2023 | 9.9% |
| BIO RAD LABS INC | 40 | Q1 2023 | 4.7% |
| BRISTOL-MYERS SQUIBB CO | 38 | Q3 2023 | 11.9% |
| BAXTER INTL INC | 34 | Q3 2023 | 12.7% |
| CARDINAL HEALTH INC | 34 | Q3 2023 | 8.1% |
| PERKINELMER INC | 33 | Q2 2021 | 6.3% |
| BIOGEN INC | 30 | Q3 2023 | 7.6% |
| ELEVANCE HEALTH INC | 30 | Q3 2023 | 5.6% |
| GILEAD SCIENCES INC | 29 | Q3 2023 | 14.0% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 4.3% |
View SECTOR GAMMA AS's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-05 |
| 13F-HR | 2023-11-06 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-12 |
| 13F-HR/A | 2023-02-08 |
| 13F-HR | 2023-02-07 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-05 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-08 |
View SECTOR GAMMA AS's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.